Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

Erik S. Knudsen, Vishnu Kumarasamy, Amanda Ruiz, Jared Sivinski, Sejin Chung, Adam Grant, Paris Vail, Shailender S. Chauhan, Tun Jie, Taylor S. Riall, Agnieszka Witkiewicz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due to any established mechanism or published biomarker. Rather, there is a KRAS-dependent rapid adaptive response that leads to the upregulation of cyclin proteins, which participate in functional complexes to mediate resistance. In vivo, the degree of response is associated with the suppression of a gene expression signature that is strongly prognostic in pancreatic cancer. Resistance is associated with an adaptive gene expression signature that is common to multiple kinase inhibitors, but is attenuated with MTOR inhibitors. Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.

Original languageEnglish (US)
JournalOncogene
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Transcriptome
Cell Cycle
Adenocarcinoma
Cyclins
Heterografts
Phosphotransferases
Up-Regulation
Biomarkers
Cell Line
Neoplasms
Proteins
Cell Plasticity
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Cell cycle plasticity driven by MTOR signaling : integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. / Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Sivinski, Jared; Chung, Sejin; Grant, Adam; Vail, Paris; Chauhan, Shailender S.; Jie, Tun; Riall, Taylor S.; Witkiewicz, Agnieszka.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

Knudsen, Erik S. ; Kumarasamy, Vishnu ; Ruiz, Amanda ; Sivinski, Jared ; Chung, Sejin ; Grant, Adam ; Vail, Paris ; Chauhan, Shailender S. ; Jie, Tun ; Riall, Taylor S. ; Witkiewicz, Agnieszka. / Cell cycle plasticity driven by MTOR signaling : integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. In: Oncogene. 2019.
@article{a0a0bc0a948844888107171fff2dff43,
title = "Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due to any established mechanism or published biomarker. Rather, there is a KRAS-dependent rapid adaptive response that leads to the upregulation of cyclin proteins, which participate in functional complexes to mediate resistance. In vivo, the degree of response is associated with the suppression of a gene expression signature that is strongly prognostic in pancreatic cancer. Resistance is associated with an adaptive gene expression signature that is common to multiple kinase inhibitors, but is attenuated with MTOR inhibitors. Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.",
author = "Knudsen, {Erik S.} and Vishnu Kumarasamy and Amanda Ruiz and Jared Sivinski and Sejin Chung and Adam Grant and Paris Vail and Chauhan, {Shailender S.} and Tun Jie and Riall, {Taylor S.} and Agnieszka Witkiewicz",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-018-0650-0",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Cell cycle plasticity driven by MTOR signaling

T2 - integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

AU - Knudsen, Erik S.

AU - Kumarasamy, Vishnu

AU - Ruiz, Amanda

AU - Sivinski, Jared

AU - Chung, Sejin

AU - Grant, Adam

AU - Vail, Paris

AU - Chauhan, Shailender S.

AU - Jie, Tun

AU - Riall, Taylor S.

AU - Witkiewicz, Agnieszka

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due to any established mechanism or published biomarker. Rather, there is a KRAS-dependent rapid adaptive response that leads to the upregulation of cyclin proteins, which participate in functional complexes to mediate resistance. In vivo, the degree of response is associated with the suppression of a gene expression signature that is strongly prognostic in pancreatic cancer. Resistance is associated with an adaptive gene expression signature that is common to multiple kinase inhibitors, but is attenuated with MTOR inhibitors. Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.

AB - Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due to any established mechanism or published biomarker. Rather, there is a KRAS-dependent rapid adaptive response that leads to the upregulation of cyclin proteins, which participate in functional complexes to mediate resistance. In vivo, the degree of response is associated with the suppression of a gene expression signature that is strongly prognostic in pancreatic cancer. Resistance is associated with an adaptive gene expression signature that is common to multiple kinase inhibitors, but is attenuated with MTOR inhibitors. Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85060786753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060786753&partnerID=8YFLogxK

U2 - 10.1038/s41388-018-0650-0

DO - 10.1038/s41388-018-0650-0

M3 - Article

C2 - 30696953

AN - SCOPUS:85060786753

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -